CITI/CALL/MODERNA/260/0.1/20.06.24 | Market Closed - Deutsche Boerse AG 18:40:10 05/06/2024 BST | ||
| 0.001 EUR | 0.00% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 05/06/24 | 0.001 | 0.00% |
| 04/06/24 | 0.001 | 0.00% |
| 03/06/24 | 0.001 | 0.00% |
| 31/05/24 | 0.001 | 0.00% |
| 30/05/24 | 0.001 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 05, 2024 at 06:40 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Citi
|
| WKN | KG58AV |
| ISIN | DE000KG58AV5 |
| Date issued | 06/07/2022 |
| Strike | 260 $ |
| Maturity | 20/06/2024 (15 Days) |
| Parity | 10 : 1 |
| Emission price | 2.34 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.11 € |
|---|---|
| Lowest since issue | 0.001 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
145.3
USD
Average target price
142.8
USD
Spread / Average Target
-1.74%
- Stock Market
- Warrants
- Warrant